Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 60 and up

Using liraglutide to prevent delirium in elderly diabetic patients after heart surgery

Official title: Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: a Single-Center Randomized Controlled Study

Run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT06361238 · Data updated 2026-11-12

This study is testing if liraglutide can help prevent confusion after heart surgery in older diabetic patients.

More Delirium - Postoperative trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages60 Years and up
SexAll
Enrollment260 (estimated)
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedNovember 19, 2024
Main results expectedMarch 31, 2027
Study endsMarch 31, 2028
Registry record updatedDecember 20, 2024
Trial IDNCT06361238 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are elderly patients aged 60 and above with Type 2 diabetes who are scheduled for elective cardiac surgery.

Probably not a fit

Patients with a history of neurological or psychiatric disorders, severe liver dysfunction, or those who are pregnant or breastfeeding may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of liraglutide, a medication commonly used for Type 2 diabetes, in preventing postoperative delirium in elderly patients undergoing cardiac surgery. Delirium is a significant complication that can lead to increased mortality and longer hospital stays. The trial will compare the effects of liraglutide injections against placebo injections in this patient population. By targeting neuroinflammation, the study aims to reduce the incidence of delirium and improve postoperative outcomes.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the occurrence of delirium in elderly diabetic patients after cardiac surgery, leading to better recovery and lower healthcare costs.

How similar studies have gone: Preliminary studies have shown promise for similar approaches, but this specific application of liraglutide in preventing postoperative delirium is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 60 years
2. Type 2 diabetes
3. Patients undergoing elective cardiac surgery

Exclusion Criteria:

1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments
3. History of central nervous system damage or surgery
4. Cardiac function NYHA Class IV
5. Severe liver dysfunction (Child-Pugh Class C)
6. Severe renal failure requiring renal replacement therapy
7. History of pancreatitis
8. Type 1 diabetes
9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
10. Patients with medullary thyroid carcinoma or a family history of it
11. Pregnant or breastfeeding women
12. Intolerance or allergy to liraglutide
13. Previous use of GLP-1A and SGLT2i
14. Patients who refuse to sign the informed consent

Where it's running

  • Wenxue liu
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

  • Principal investigator: Dongjin Wang, PhD,MD — Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
  • Study coordinator: Wenxue Liu, PhD,MD
  • Email: diligent_hi@163.com
  • Phone: 15751866806

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.